222 related articles for article (PubMed ID: 22538017)
1. Enhancement of radiation response with bevacizumab.
Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
J Exp Clin Cancer Res; 2012 Apr; 31(1):37. PubMed ID: 22538017
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
[TBL] [Abstract][Full Text] [Related]
3. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
4. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of radiation response with the vascular targeting agent ZD6126.
Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1458-65. PubMed ID: 16488554
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.
Lee SY; Kim DK; Cho JH; Koh JY; Yoon YH
Arch Ophthalmol; 2008 Jul; 126(7):953-8. PubMed ID: 18625942
[TBL] [Abstract][Full Text] [Related]
7. Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.
Sudaka A; Susini A; Lo Nigro C; Fischel JL; Toussan N; Formento P; Tonissi F; Lattanzio L; Russi E; Etienne-Grimaldi MC; Merlano M; Milano G
Invest New Drugs; 2013 Feb; 31(1):59-65. PubMed ID: 22714791
[TBL] [Abstract][Full Text] [Related]
8. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
[TBL] [Abstract][Full Text] [Related]
10. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
[TBL] [Abstract][Full Text] [Related]
11. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
Inoue S; Hartman A; Branch CD; Bucana CD; Bekele BN; Stephens LC; Chada S; Ramesh R
Mol Ther; 2007 Feb; 15(2):287-94. PubMed ID: 17235306
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
14. Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation.
Zeitlin BD; Spalding AC; Campos MS; Ashimori N; Dong Z; Wang S; Lawrence TS; Nör JE
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):879-87. PubMed ID: 20675079
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
16. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
Huang SM; Li J; Armstrong EA; Harari PM
Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
[TBL] [Abstract][Full Text] [Related]
17. Modulation of bevacizumab-induced toxicity for cultured human corneal fibroblasts.
Kim EK; Kang SW; Kim JY; Min K; Kim TI
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):3922-31. PubMed ID: 23640039
[TBL] [Abstract][Full Text] [Related]
18. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer.
Lee SJ; Lee I; Lee J; Park C; Kang WK
Br J Cancer; 2014 Jul; 111(3):497-505. PubMed ID: 24945998
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
[TBL] [Abstract][Full Text] [Related]
20. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
